Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

If budget issues, delayed payments, or slow cash flow got you stressed, expect progress. Time to put those big ideas into action and make them a reality. The February 27 Pisces new moon ...

Some types are more aggressive and progress faster. A timeline also depends on overall ... The early stages of lung cancer often have no obvious symptoms. By the time symptoms are noticeable, cancer ...

Drop in, dependency-free progress bars for your Django/Celery applications. Super simple setup. Lots of customization available. Then in the page you want to show the progress bar you just do the ...

With respect to climate change, 2024 was in many ways similar to 2023: Manifestations of a changed climate continued to be felt increasingly across the world, even as the clean-energy transition ...